Age-Related Macular Degeneration (AMD) Therapeutics Market Size to Grow by USD 7.92 billion | High Prevalence of AMD to Drive Growth

Request Latest Sample Report for additional highlights related to the growth of the age-related macular degeneration (AMD) therapeutics market

Age-Related Macular Degeneration (AMD) Therapeutics Mdarket 2021-2025: Scope

The age-related macular degeneration (AMD) therapeutics market report covers the following areas:

Subscribe to our “Basic Plan” billed annually at USD 5000. Get lifetime access to our Technavio Insights

Age-Related Macular Degeneration (AMD) Therapeutics Market 2021-2025: Vendor Analysis

The age-related macular degeneration (AMD) therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Alkeus Pharmaceuticals Inc., Allegro Ophthalmics LLC, Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics Inc., and Reliance Industries Ltd. are among some of the major market participants.

To learn more about key vendors operating in the age-related macular degeneration (AMD) therapeutics market and their offerings, Download a Sample Report

Age-Related Macular Degeneration (AMD) Therapeutics Market 2021-2025: Segmentation

  • Type
  • Wet AMD: The wet AMD segment will have significant market share growth during the forecast period. People who have wet AMD can see a dark spot in the center of their vision due to blood or fluid under the macula. The growth of this segment is mainly attributed to the increasing use of vascular endothelial growth factor (VEGF) inhibitors, which are largely used for the treatment of wet AMD.
  • Dry AMD
  • Geography
  • North America: North America will account for 40% of the market’s growth during the forecast period. The aging baby boomer population will drive the growth of the age-related macular degeneration (AMD) therapeutics market in North America during the forecast period.
  • Europe
  • Asia
  • ROW

Age-Related Macular Degeneration (AMD) Therapeutics Market 2021-2025: Key Highlights

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will assist age-related macular degeneration (AMD) therapeutics market growth during the next five years
  • Estimation of the age-related macular degeneration (AMD) therapeutics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the age-related macular degeneration (AMD) therapeutics market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of age-related macular degeneration (AMD) therapeutics market vendors

Related Reports

Automated Microscopy Market by Type and Geography – Forecast and Analysis 2022-2026

Single-use Bioprocessing System Market by Product, Application, End-user, and Geography – Forecast and Analysis 2022-2026

Age-Related Macular Degeneration (AMD) Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 11.96%

Market growth 2021-2025

USD 7.92 billion

Market structure

Fragmented

YoY growth (%)

10.80

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Alkeus Pharmaceuticals Inc., Allegro Ophthalmics LLC, Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics Inc., and Reliance Industries Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period,

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

***1. Executive Summary                         

***2. Market Landscape                            

               **2.1 Market ecosystem             

                              *Exhibit 01:  Parent market

                              *Exhibit 02:  Market characteristics

               **2.2 Value chain analysis           

                              *Exhibit 03:  Value Chain Analysis: Life sciences tools and services

                              *2.2.1 Research and development

                              *2.2.2 Inputs

                              *2.2.3 Production

                              *2.2.4 Distribution

                              *2.2.5 Marketing and sales

                              *2.2.6 Post-sales and services

                              *2.2.7 Industry innovations

***3. Market Sizing                      

               **3.1 Market definition

                              *Exhibit 04:  Offerings of vendors included in the market definition

               **3.2 Market segment analysis  

                              *Exhibit 05:  Market segments

               **3.3 Market size 2020 

               **3.4 Market outlook: Forecast for 2020 – 2025 

                              *Exhibit 06:  Global – Market size and forecast 2020 – 2025 ($ million)

                              *Exhibit 07:  Global market: Year-over-year growth 2020 – 2025 (%)

***4. Five Forces Analysis                         

               **4.1 Five Forces Summary         

                              *Exhibit 08:  Five forces analysis 2020 & 2025

               **4.2 Bargaining power of buyers            

                              *Exhibit 09:  Bargaining power of buyers

               **4.3 Bargaining power of suppliers        

                              *Exhibit 10: Bargaining power of suppliers

               **4.4 Threat of new entrants     

                              *Exhibit 11:  Threat of new entrants

               **4.5 Threat of substitutes          

                              *Exhibit 12: Threat of substitutes

               **4.6 Threat of rivalry   

                              *Exhibit 13: Threat of rivalry

               **4.7 Market condition 

                              *Exhibit 14:  Market condition – Five forces 2020

***5. Market Segmentation by Type                    

               **5.1 Market segments

                              *The segments covered in this chapter are:

                              *Exhibit 15:  Type – Market share 2020-2025 (%)

               **5.2 Comparison by Type          

                              *Exhibit 16:  Comparison by Type

               **5.3 Wet AMD – Market size and forecast 2020-2025    

                              *Exhibit 17:  Wet AMD – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 18:  Wet AMD – Year-over-year growth 2020-2025 (%)

               **5.4 Dry AMD – Market size and forecast 2020-2025      

                              *Exhibit 19:  Dry AMD – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 20:  Dry AMD – Year-over-year growth 2020-2025 (%)

               **5.5 Market opportunity by Type          

                              *Exhibit 21:  Market opportunity by Type

***6. Customer landscape                        

                              *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                              *Exhibit 22:  Customer landscape

***7. Geographic Landscape                    

               **7.1 Geographic segmentation

                              *The regions covered in the report are:

  • *North America
  • *Europe
  • *Asia
  • *ROW

                              *Exhibit 23:  Market share by geography 2020-2025 (%)

               **7.2 Geographic comparison    

                              *Exhibit 24:  Geographic comparison

               **7.3 North America – Market size and forecast 2020-2025          

                              *Exhibit 25:  North America – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 26:  North America – Year-over-year growth 2020-2025 (%)

               **7.4 Europe – Market size and forecast 2020-2025         

                              *Exhibit 27:  Europe – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 28:  Europe – Year-over-year growth 2020-2025 (%)

               **7.5 Asia – Market size and forecast 2020-2025

                              *Exhibit 29:  Asia – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 30:  Asia – Year-over-year growth 2020-2025 (%)

               **7.6 ROW – Market size and forecast 2020-2025             

                              *Exhibit 31:  ROW – Market size and forecast 2020-2025 ($ million)

                              *Exhibit 32:  ROW – Year-over-year growth 2020-2025 (%)

               **7.7 Key leading countries        

                              *Exhibit 33:  Key leading countries

               **7.8 Market opportunity by geography

                              *Exhibit 34:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                  

               **8.1 Market drivers      

                              *8.1.1 High prevalence of AMD

                              *8.1.2 Rising approvals of therapeutics for AMD

                              *8.1.3 Rising geriatric population

               **8.2 Market challenges              

                              *8.2.1 Lack of approved therapies for dry AMD

                              *8.2.2 Side effects of available therapeutics

                              *Exhibit 35:  Side effects of AMD therapeutics

                              *8.2.3 Expiry of patents on major therapeutics

                              *Exhibit 36:  Impact of drivers and challenges

               **8.3 Market trends      

                              *8.3.1 Strategic alliances

                              *8.3.2 Development of gene therapy for AMD

                              *8.3.3 Growing awareness about AMD

***9. Vendor Landscape                            

                              *Exhibit 37:  Vendor landscape

               **9.1 Landscape disruption         

                              *Exhibit 38:  Landscape disruption

                              *Exhibit 39:  Industry risks

               **9.2 Competitive Scenario        

***10. Vendor Analysis               

               **10.1 Vendors covered              

                              *Exhibit 40:  Vendors covered

               **10.2 Market positioning of vendors    

                              *Exhibit 41: Market positioning of vendors

               **10.3 Alkeus Pharmaceuticals Inc.         

                              *Exhibit 42:  Alkeus Pharmaceuticals Inc.  – Overview

                              *Exhibit 43:  Alkeus Pharmaceuticals Inc.  – Product and service

                              *Exhibit 44:  Alkeus Pharmaceuticals Inc.  – Key offerings

               **10.4 Allegro Ophthalmics LLC

                              *Exhibit 45:  Allegro Ophthalmics LLC – Overview

                              *Exhibit 46:  Allegro Ophthalmics LLC – Product and service

                              *Exhibit 47:  Allegro Ophthalmics LLC – Key offerings

               **10.5 Amgen Inc.

                              *Exhibit 48:  Amgen Inc. – Overview

                              *Exhibit 49:  Amgen Inc. – Business segments

                              *Exhibit 50:  Amgen Inc. – Key offerings

               **10.6 Apellis Pharmaceuticals Inc.        

                              *Exhibit 51:  Apellis Pharmaceuticals Inc. – Overview

                              *Exhibit 52:  Apellis Pharmaceuticals Inc. – Product and service

                              *Exhibit 53:  Apellis Pharmaceuticals Inc. – Key offerings

               **10.7 Bausch Health Companies Inc.    

                              *Exhibit 54:  Bausch Health Companies Inc. – Overview

                              *Exhibit 55:  Bausch Health Companies Inc. – Business segments

                              *Exhibit 56:  Bausch Health Companies Inc. – Key news

                              *Exhibit 57:  Bausch Health Companies Inc. – Key offerings

                              *Exhibit 58:  Bausch Health Companies Inc. – Segment focus

               **10.8 Bayer AG             

                              *Exhibit 59:  Bayer AG – Overview

                              *Exhibit 60:  Bayer AG – Business segments

                              *Exhibit 61:  Bayer AG – Key offerings

                              *Exhibit 62:  Bayer AG – Segment focus

               *10.9 F. Hoffmann-La Roche Ltd.

               *Exhibit 63:  F. Hoffmann-La Roche Ltd. – Overview          

               *Exhibit 64:  F. Hoffmann-La Roche Ltd. – Business segments        

               *Exhibit 65:  F. Hoffmann-La Roche Ltd. – Key offerings   

               *Exhibit 66:  F. Hoffmann-La Roche Ltd. – Segment focus

               **10.10 Novartis AG      

                              *Exhibit 67:  Novartis AG – Overview

                              *Exhibit 68:  Novartis AG – Business segments

                              *Exhibit 69:  Novartis AG – Key offerings

                              *Exhibit 70:  Novartis AG – Segment focus

               **10.11 Outlook Therapeutics Inc.          

                              *Exhibit 71:  Outlook Therapeutics Inc.  – Overview

                              *Exhibit 73:  Outlook Therapeutics Inc.  – Key offerings

               **10.12 Reliance Industries Ltd.

                              *Exhibit 74:  Reliance Industries Ltd. – Overview

                              *Exhibit 75:  Reliance Industries Ltd. – Business segments

                              *Exhibit 76:  Reliance Industries Ltd. – Key offerings

                              *Exhibit 77:  Reliance Industries Ltd. – Segment focus

***11. Appendix                           

               **11.1 Scope of the report         

                              *11.1.1 Market definition

                              *11.1.2 Objectives

                              *11.1.3 Notes and caveats

               **11.2 Currency conversion rates for US$            

                              *Exhibit 78:  Currency conversion rates for US$

               **11.3 Research Methodology   

                              *Exhibit 79:  Research Methodology

                              *Exhibit 80:  Validation techniques employed for market sizing

                              *Exhibit 81:  Information sources

               **11.4 List of abbreviations        

                              *Exhibit 82:  List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

Next Post

Meta Makes Changes to Marketing Strategy Amid Scandals

Since the spring, the social media company formerly known as Facebook has been evaluating where it advertises and how much it spends doing so, taking pitches from agencies that want to help manage its enormous marketing budget. The so-called media review — the first for Meta, the new parent company […]

Subscribe US Now